lexapro tablet 10 mg
lundbeck singapore pte. ltd. - escitalopram - tablet, film coated - 10 mg - escitalopram 10 mg
lexapro tablet 15 mg
lundbeck singapore pte. ltd. - escitalopram - tablet, film coated - 15 mg - escitalopram 15 mg
lexapro tablet 20 mg
lundbeck singapore pte. ltd. - escitalopram - tablet, film coated - 20 mg - escitalopram 20 mg
lexapro tablet 5 mg
lundbeck singapore pte. ltd. - escitalopram - tablet, film coated - 5 mg - escitalopram 5 mg
lexapro escitalopram oxalate tablet
cardinal health - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 10 mg
lexapro escitalopram oxalate tablet film coated
lake erie medical dba quality care products llc - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 10 mg
lexapro escitalopram oxalate tablet film coated
cardinal health - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 10 mg
lexapro escitalopram oxalate tablet film coated
bryant ranch prepack - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 10 mg
lexapro escitalopram oxalate tablet film coated
unit dose services - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 10 mg
escitalopram solution
macleods pharmaceuticals limited - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 5 mg in 5 ml - escitalopram oral solution is indicated for the treatment of: • major depressive disorder (mdd) in adults and pediatric patients 12 years of age and older. • generalized anxiety disorder (gad) in adults. additional pediatric use information is approved for abbvie inc.’s lexapro (escitalopram) tablets and lexapro (escitalopram) oral solution. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that information. escitalopram is contraindicated in patients: • taking maois with escitalopram or within 14 days of stopping treatment with escitalopram because of an increased risk of serotonin syndrome. the use of escitalopram within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.7), and warnings and precautions (5.2)] . starting escitalopram in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of se